Endovascular treatment with interwoven nitinol stent for common femoral artery lesions: 2-year outcomes of a single center experience

Abstract

Objective

The study aimed was to report 2-year outcomes of endovascular treatment with interwoven nitinol (Supera™) stent for common femoral artery (CFA) lesions.

Methods

We reviewed the clinical data of 20 patients who presented with CFA stenosis or occlusion and underwent balloon angioplasty followed by Supera™ stenting in CFA between February 2016 and January 2022. The outcomes were evaluated in these patients in terms of technical success, post-intervention complications, reintervention, and cumulative patency (1 year, and 2 years).

Results

The study included 20 patients (22 lesions) who presented with isolated CFA lesions (3), iliac lesions involving CFA (6), superficial femoral artery (SFA) lesions involving CFA (8), and extensive lesions from the iliac artery to SFA (5). There were 16 men (80%) with a mean age of 69.7 years (range, 34–83). Hypertension, smoking, and diabetes were found in 15 (75%), 7 (35%), and 7 patients (35%), respectively. Clinical presentations were Rutherford stage 5 (9, 45%), Rutherford stage 4 (5, 25%), Rutherford stage 6 (4, 20%), and Rutherford stage 3 (2, 10%). Technical success was achieved in all patients (100%). The procedures for treatment were isolated CFA Supera™ stenting (1, 4.5%), CFA plus DFA Supera™ stenting (jailed SFA) (2, 9.1%), CFA plus SFA Supera™ stenting (jailed DFA) (8, 36.4%), CFA Supera™ stenting plus bare iliac stenting (Astron) (6, 27.3%), CFA plus SFA Supera™ stenting (jailed DFA) plus bare iliac stenting (Astron) (5, 22.7%), and additional DFA angioplasty (7, 31.8%). The rate of in-hospital mortality and morbidity were 0% and 10%, respectively. Distal embolization after pre-dilatation occurred in 1 patient, and cerebral infarction occurred 12 h after the procedure in 1 patient. The mean follow-up time was 23 months (range, 2–64). During the follow-up period, in-stent occlusion occurred in 2 patients at 9 and 46 months. Re-intervention was performed in 1 patient due to recurrent symptom of claudication. The cumulative primary patency at 1 year and 2 years were 93.3% and 93.3%, respectively.

Conclusion

Endovascular treatment with interwoven nitinol (Supera™) stent for CFA lesions was associated with acceptable outcomes at 2 years.

Keywords

Interwoven nitinol stent Supera™ stent common femoral endarterectomy common femoral artery stenting endovascular treatment

Get full access to this article

View all access options for this article.

References

Malgor

Ricotta

II Bower

, et al. Common femoral artery endarterectomy for lower-extremity ischemia: evaluating the need for additional distal limb revascularization. Ann Vasc Surg 2012; 26(7): 946–956.

Siracuse

Gill

Schneider

, et al. Assessing the perioperative safety of common femoral endarterectomy in the endovascular era. Vasc Endovasc Surg 2014; 48(1): 27–33.

Nguyen

Amdur

Abugideiri

, et al. Postoperative complications after common femoral endarterectomy. J Vasc Surg 2015; 61(6): 1489–1494.

Changal

Syed

Dar

, et al. Systematic review and proportional meta-analysis of endarterectomy and endovascular therapy with routine or selective stenting for common femoral artery atherosclerotic disease. J Intervent Cardiol 2019; 2019: 1–12.

Stricker

Spinedi

Limoni

, et al. Stent-assisted angioplasty (SAA) at the level of the common femoral artery bifurcation: long-term outcomes. Cardiovasc Intervent Radiol 2020; 43(4): 541–546.

Tao

Gotra

Tan

, et al. SUPERA stenting in the common femoral artery: early experience and practical considerations. Vasc Endovasc Surg 2022; 56(4): 357–368.

Gouëffic

Della Schiava

Thaveau

, et al. Stenting or surgery for de novo common femoral artery stenosis. JACC Cardiovasc Interv 2017; 10(13): 1344–1354.

Mehta

Zhou

Paty

, et al. Percutaneous common femoral artery interventions using angioplasty, atherectomy, and stenting. J Vasc Surg 2016; 64(2): 369–379.

Setacci

De Donato

Teraa

, et al. Chapter IV: treatment of critical limb ischaemia. Eur J Vasc Endovasc Surg 2011; 42(Suppl 2): S43–S59.

10.

Thiney

Millon

Boudjelit

, et al. Angioplasty of the common femoral artery and its bifurcation. Ann Vasc Surg 2015; 29(5): 960–967.

11.

Bishu

Armstrong

. Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag 2015; 11: 387–395.

12.

Ruiz

San Norberto García

Domingos

, et al. Supera stent in popliteal artery, 2 years follow-up results. Eur J Vasc Endovasc Surg 2019; 58(6): e455.

13.

Dalai

Narayana

Pati

, et al. Supera stent for management of occlusive popliteal artery disease: an Indian experience. Indian J Surg 2021; 83(2): 487–494.

14.

San Norberto

Flota

Fidalgo-Domingos

, et al. Real-world results of supera stent implantation for popliteal artery atherosclerotic lesions: 3-year outcome. Ann Vasc Surg 2020; 62: 397–405.

15.

Elbadawy

Ali

Saleh

. Midterm outcomes of common femoral endarterectomy combined with inflow and outflow endovascular treatment for chronic limb threatening ischaemia. Eur J Vasc Endovasc Surg 2020; 59(6): 947–955.

16.

Azéma

Davaine

Guyomarch

, et al. Endovascular repair of common femoral artery and concomitant arterial lesions. Eur J Vasc Endovasc Surg 2011; 41(6): 787–793.

17.

Donas

Pitoulias

Schwindt

, et al.

Endovascular treatment of profunda femoris artery obstructive disease: nonsense or useful tool in selected cases?

Eur J Vasc Endovasc Surg 2010; 39(3): 308–313.

18.

Chi

Ding

. Application of combined superficial femoral artery stenting and deep femoral artery profundoplasty in Chinese patients with lower extremity artery disease. Front Surg 2021; 8: 646978.

19.

Lugenbiel

Grebner

Zhou

, et al. Treatment of femoropopliteal lesions with the AngioSculpt scoring balloon–results from the Heidelberg PANTHER registry. Vasa 2018; 47: 49–55.

20.

Low

Shih

, et al. Midterm results of the supera stent for the treatment of femoropopliteal occlusive disease. Ann Vasc Surg 2022; 86: 177–183.

21.

Yang

Shi

, et al. Treatment of atherosclerotic femoropopliteal artery disease with supera interwoven nitinol stent: a real-world study in China. Ann Vasc Surg 2022; 85: 183–189.

22.

Garcia

Jaff

Metzger

, et al. Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB trial. Circ Cardiovasc Interv 2015; 8(5): e000937.

23.

Nasr

Gouailler

Marret

, et al. Treatment of long femoropopliteal lesions with self-expanding interwoven nitinol stent: 24 month outcomes of the STELLA-SUPERA trial. J Endovasc Ther 2022; 30(1): 98–105.

24.

Saratzis

Stavroulakis

. Contemporary endovascular management of common femoral artery atherosclerotic disease. Br J Surg 2021; 108: 882–884.

25.

Stavroulakis

Schwindt

Torsello

, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther 2017; 24(2): 181–188.